Literature DB >> 24700496

Clinical significance of expression and epigenetic profiling of TUSC1 in gastric cancer.

Mitsuro Kanda1, Dai Shimizu, Shuji Nomoto, Soki Hibino, Hisaharu Oya, Hideki Takami, Daisuke Kobayashi, Suguru Yamada, Yoshikuni Inokawa, Chie Tanaka, Tsutomu Fujii, Hiroyuki Sugimoto, Masahiko Koike, Michitaka Fujiwara, Yasuhiro Kodera.   

Abstract

BACKGROUND AND OBJECTIVES: The prognosis of advanced gastric cancer (GC) remains dismal. The aim of this study was to identify a novel tumor suppressor gene (TSG) with repressed transcription by aberrant DNA methylation in GC.
METHODS: The expression and methylation status of tumor suppressor candidate 1 (TUSC1) were evaluated in GC cell lines and 112 pairs of surgical specimens. TUSC1 protein expression and distribution in GC tissue were determined by immunohistochemistry.
RESULTS: The majority of GC cell lines (83%) and GC tissues (82%) showed downregulation of TUSC1 mRNA compared with noncancerous tissues. No significant differences were found in TUSC1 mRNA expression between three GC subtypes categorized by tumor locations and morphology. Reduced expression of TUSC1 mRNA in GC tissues was significantly associated with advanced T stage, vessel invasion and lymph node metastasis, leading to poor prognosis. The expression patterns of TUSC1 protein were confirmed to be consistent with those of TUSC1 mRNA. Sixty-three (57%) of 112 patients showed intragenic hypermethylation of TUSC1 in GC tissues.
CONCLUSIONS: Our results suggested that reduced expression of TUSC1 mRNA was related to poor prognosis and TUSC1 is a putative TSG that is suppressed through intragenic hypermethylation in GC.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  TUSC1; expression; gastric cancer; intragenic methylation; tumor suppressor

Mesh:

Substances:

Year:  2014        PMID: 24700496     DOI: 10.1002/jso.23614

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  17 in total

1.  Adverse prognostic impact of perioperative allogeneic transfusion on patients with stage II/III gastric cancer.

Authors:  Mitsuro Kanda; Daisuke Kobayashi; Chie Tanaka; Naoki Iwata; Suguru Yamada; Tsutomu Fujii; Goro Nakayama; Hiroyuki Sugimoto; Masahiko Koike; Shuji Nomoto; Kenta Murotani; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  Gastric Cancer       Date:  2015-01-07       Impact factor: 7.370

Review 2.  Recent advances in the molecular diagnostics of gastric cancer.

Authors:  Mitsuro Kanda; Yasuhiro Kodera
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

3.  Tumor Suppressor Candidate 1 Suppresses Cell Growth and Predicts Better Survival in Glioblastoma.

Authors:  Rui Zhang; Wan Yu; Guanyu Liang; Zhanjun Jia; Zhengxin Chen; Lin Zhao; Yongsheng Yuan; Xiaobin Zhou; Daqian Li; Shuying Shen; Ning Liu; Aihua Zhang; Huibo Wang; Gang Wang
Journal:  Cell Mol Neurobiol       Date:  2016-02-20       Impact factor: 5.046

4.  Diversity of clinical implication of B-cell translocation gene 1 expression by histopathologic and anatomic subtypes of gastric cancer.

Authors:  Mitsuro Kanda; Hisaharu Oya; Shuji Nomoto; Hideki Takami; Dai Shimizu; Ryoji Hashimoto; Satoshi Sueoka; Daisuke Kobayashi; Chie Tanaka; Suguru Yamada; Tsutomu Fujii; Goro Nakayama; Hiroyuki Sugimoto; Masahiko Koike; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  Dig Dis Sci       Date:  2014-12-09       Impact factor: 3.199

Review 5.  Molecular mechanisms of peritoneal dissemination in gastric cancer.

Authors:  Mitsuro Kanda; Yasuhiro Kodera
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

6.  Dihydropyrimidinase-like 3 is a putative hepatocellular carcinoma tumor suppressor.

Authors:  Hisaharu Oya; Mitsuro Kanda; Hiroyuki Sugimoto; Dai Shimizu; Hideki Takami; Soki Hibino; Ryoji Hashimoto; Yukiyasu Okamura; Suguru Yamada; Tsutomu Fujii; Goro Nakayama; Masahiko Koike; Shuji Nomoto; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  J Gastroenterol       Date:  2014-08-31       Impact factor: 7.527

7.  NRAGE promotes the malignant phenotype of hepatocellular carcinoma.

Authors:  Dai Shimizu; Mitsuro Kanda; Hiroyuki Sugimoto; Satoshi Sueoka; Hideki Takami; Kazuhiro Ezaka; Yuri Tanaka; Ryoji Hashimoto; Yukiyasu Okamura; Naoki Iwata; Chie Tanaka; Suguru Yamada; Tsutomu Fujii; Goro Nakayama; Masahiko Koike; Shuji Nomoto; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  Oncol Lett       Date:  2016-01-15       Impact factor: 2.967

8.  Combined treatment of human multiple myeloma cells with bortezomib and doxorubicin alters the interactome of 20S proteasomes.

Authors:  Alexey G Mittenberg; Valeria O Kuzyk; Sergey V Shabelnikov; Daria P Gorbach; Alla N Shatrova; Olga A Fedorova; Nickolai A Barlev
Journal:  Cell Cycle       Date:  2018-08-01       Impact factor: 4.534

Review 9.  Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma.

Authors:  Mitsuro Kanda; Hiroyuki Sugimoto; Yasuhiro Kodera
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

10.  Association of TUSC1 and DPF3 gene polymorphisms with male infertility.

Authors:  Youichi Sato; Chise Hasegawa; Atsushi Tajima; Shiari Nozawa; Miki Yoshiike; Eitetsue Koh; Jiro Kanaya; Mikio Namiki; Kiyomi Matsumiya; Akira Tsujimura; Kiyoshi Komatsu; Naoki Itoh; Jiro Eguchi; Aiko Yamauchi; Teruaki Iwamoto
Journal:  J Assist Reprod Genet       Date:  2017-10-03       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.